Voleon Capital Management
ALXN

Voleon Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Voleon Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-25,000
Closed -$2.45M – 245
2019
Q3 		$2.45M Hold
25,000
– – 0.19% 87
2019
Q2 		$3.27M Buy
+25,000
New +$3.22M 0.19% 97

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Voleon Capital Management's ALXN Position: Q4 2019 in Review

Voleon Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 25,000 shares — an estimated $2.45M sold.

Voleon Capital Management first reported a position in ALXN in Q2 2019 and held it in 2 quarters. The position peaked at $3.27M in Q2 2019. 669 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Voleon Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Voleon Capital Management sold 25,000 Alexion Pharmaceuticals shares in Q4 2019, an estimated $2.45M.
  • Voleon Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Voleon Capital Management's Alexion Pharmaceuticals position peaked at $3.27M in Q2 2019.
  • 669 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Voleon Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.